Flomoxef

Summary

Flomoxef (CHEMBL15413) is a phase-3 clinical-stage small-molecule antibacterial drug (ATC J01DC14); indicated across 2 conditions including urinary tract infection and bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01DC14
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 496.5 Da · C15H18F2N6O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL15413
Name	Flomoxef
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65864
ChEBI	CHEBI:135813
ATC	J01DC14
Molecular formula	C15H18F2N6O7S2
Molecular weight	496.5
InChIKey	UHRBTBZOWWGKMK-DOMZBBRYSA-N

SMILES: CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSC3=NN=NN3CCO)C(=O)O)NC(=O)CSC(F)F

IUPAC name: (6R,7R)-7-[[2-(difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A second-generation oxacephem antibiotic in which the oxazine ring is substituted at C-3 with a hydroxyethyl-substituted tetrazolylthiomethyl group and the azetidinone ring carries 7α-methoxy and 7β-{2-[(difluoromethyl)thiomethyl]acetamido} substituents.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Flomoxef, FLOMOXEF

Patent coverage: 1,522 distinct patent families (6,029 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	3	MONDO:0100338	EFO:0003103
bacterial infectious disease	3	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02302092	PHASE3	TERMINATED	An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).